@GSVLab

Laboratory focused on molecular mechanisms that cause neurodegeneration. Interested in developing therapies & biomarkers for ALS, HD, & XDP. Co-founder @in_pwn.

 Boston, MA
mghmind.org/faculty/Sadri-Vakili
Joined January 2019
  • Tweets1K
  • Following437
  • Followers486
99Media
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
Wicked fun project to work on during my time @mtholyoke in Dr. Ken Colodner's lab. Happy to see the tracheal system get some recognition!
FlyWire@FlyWireNews30 Jun 2023
4 years. 250 people. 2.7 million edits to proofread 127,000 neurons. The fly connectome is here! Preprint: Neuronal wiring diagram of an adult brain biorxiv.org/content/10.1101/… Explore it in Codex: codex.flywire.ai/
2
5
608
Sadri-Vakili lab retweeted
MGH Neurology@MGHNeurology12 Jun 2023
We were thrilled to work with @nytimes on a story about the fantastic work and collaboration that is done at our institution every day. Read the full article here: bit.ly/3J7ZJY5
2
6
812
Checkout our preprint in @medrxivpreprint focused on #tau and #HD. Congratulations to first author @tpetrozziello for her tremendous leadership and efforts. Heartfelt thank you to patients, families, and our superb collaborators! @neuro_huntress @AyleenCT medrxiv.org/content/10.1101/…

Age-dependent increase in tau phosphorylation at serine 396 in Huntington’s disease pre-frontal...

Background To date, it is still controversial whether tau phosphorylation plays a role in Huntington’s disease (HD), as previous studies demonstrated either no alterations or increases in phosphory...

medrxiv.org
5
2
11
1,236
Sadri-Vakili lab retweeted
MGH Neurology@MGHNeurology26 Apr 2023
We are thrilled that the FDA has approved Tofersen for SOD1 ALS! Tofersen becomes the second approved therapy for ALS in less than a year. Read the Healey & AMG Center's full announcement: massgeneral.org/neurology/al…
11
1
49
4,987
Sadri-Vakili lab retweeted
Brian Wallach
@bsw502025 Apr 2023
It happened. Today, @US_FDA granted accelerated approval for Tofersen. This is a huge day for the entire ALS community and, in particular, the families who have SOD1-ALS. Today, they finally have some hope. fda.gov/drugs/news-events-hu…

FDA approves treatment of ALS associated with a mutation in the supero

FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense...

fda.gov
160
453
50
7,615
167,441
Load more